MWN 109
Alternative Names: MWN-109Latest Information Update: 25 Aug 2026
At a glance
- Originator Shanghai Minwei Biotechnology
- Class Antihyperglycaemics; Fatty acids; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Obesity; Type 2 diabetes mellitus
- Preclinical Non-alcoholic fatty liver disease
Most Recent Events
- 21 Aug 2026 Shanghai Minwei Biotechnology plans a phase III trial for Obesity in China (SC) (NCT07778693)
- 10 Aug 2026 Shanghai Minwei Biotechnology completes phase I trial in Obesity and Type 2 diabetes mellitus (In volunteers) in China (NCT07801326)
- 09 Jul 2026 Shanghai Minwei Biotechnology completes a phase II trial in Obesity in China (PO) (NCT07791524) (CTR20260203)